Spots Global Cancer Trial Database for Development and Validation of The Post-RT LARS Prediction Model (PORTLARS)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Development and Validation of The Post-RT LARS Prediction Model (PORTLARS)

Official Title: Development and Validation of a Nomogram to Predict Severe Bowel Dysfunction After Rectal Cancer Resection and Neoadjuvant Radiotherapy: A Multicenter, Observational Clinical Study

Study ID: NCT05129215

Conditions

Low Anterior Resection Syndrome

Radiotherapy

Rectal Cancer

Interventions

Questionnaire

Study Description

Brief Summary: Bowel dysfunction is common after a restorative rectal cancer resection. Neoadjuvant radiotherapy is an influential factor that impairs bowel function and quality of life. However, almost half patients who have received primary surgery with preoperative radiotherapy are able to restore a good or moderate bowel function in the long term. This multicenter observational study aims to identify the risk factors of severe bowel dysfunction after rectal cancer resection and neoadjuvant radiotherapy, in accordance with the LARS score, and to build a model that predicts long-term major LARS in the early stage of follow-up. Development and validation cohorts are enrolled from tertiary hospitals in China.

Detailed Description: